ArticleZeitschrift fur Rheumatologie2025
[Immunoadsorption in rheumatic autoimmune diseases: an alternative treatment option : Retrospective insights on the clinical application from the Rhineland-Palatinate Rheumatology Center].
Article in Zeitschrift fur Rheumatologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic inflammatory rheumatic diseases are frequently linked to significant morbidity and, in some cases, can lead to severe, chronic disease courses. Early and effective treatment strategies are required to prevent irreversible damage. Drug-based immunosuppression is not possible for all patients. In such cases the use of alternative treatment, such as immunoadsorption (IA) is of particular interest. Despite positive clinical experiences, the data on the use of IA in rheumatic diseases are limited.
objectiveThe aim was to analyze the application, efficacy and safety of IA under routine conditions. MATERIAL AND
methodsIn this retrospective study immunoadsorption (IA) treatment was performed 373 times in 31 patients with various rheumatic diseases. RESULTS AND DISCUSSION: The results show that IA was predominantly used in combination with other medicinal procedures, often as a bridging therapy or as a last resort in complex cases. The treatment showed a good safety profile: 25% of patients experienced mainly mild side effects such as a short-term drops in blood pressure. The use of IA led to a significant reduction in immunoglobulin levels. A positive clinical therapeutic effect was observed in 48% of the cases. Shorter intervals between treatments were associated with a better clinical response (p = 0.004). A correlation between a positive therapeutic effect and the concomitant glucocorticoid therapy could not be established (p = 0.611), which could potentially indicate an independent effect of IA.
conclusionThe use of IA can be a valuable addition to individualized treatment approaches and should be further evaluated in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.